SPECIALTY MEDICAL CANNABIS COMPANY

Transcription

1 SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: info@revivethera.com

2 Forward looking statements Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as may, will, should, expect, plan, anticipate, believe, intend, estimate, predict, potential, continue or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

3 Revive Therapeutics Commercializing best-in-class CBD (Cannabidiol) wellness products Pharmaceutical cannabinoid programs - FDA orphan drug designation approvals First mover advantage Hemp-based CBD Gum Experienced management team in drug delivery, consumer packaged goods Robust patent portfolio cannabis gum, delivery system, method of use Near-term revenue opportunity with significant upside growth potential

4 Global Cannabis Market & Drivers $180 Billion total addressable market 1 More countries moving towards legalization Demand for unique & validated products Significant research growth of cannabis Emergence of Cannabis for wellness, Increasing acceptance Health conscious consumers, rapidly aging population, healthcare costs, opioid risks 1 At Maturity, Source: Eight Capital, The Value Case for Investing in the Cannabis Sector.

5 Disrupting the Canadian Cannabis Market $5-$9 Billion $1.3 Billion Recreational / Wellness market opportunity 1 Medical market opportunity2 1 Deloitte Report: Recreational Marijuana Insights and Opportunities. 2 Health Canada (estimated by 2024)

6 Hemp-based CBD Chewing Gum ü Patented-Protected, Clinically-tested Microencapsulated, patented in Canada and USA. FDA clinical studies. ü Best-in-class, First Mover Advantage First & only full-spectrum hemp-based CBD gum Yet there are +100 brands and +1,000 products of dried flower and oils ü Differentiated and Improved Delivery Alternative to inhale/oral with better safety & efficacy Potential to capture 40% with difficult swallowing and avoid inhalation Full Spectrum 50 mg of hemp oil and 10 mg of CBD containing natural phytocannabinoids

7 Cannabis Gum - A Better Alternative Gum Dried Flower Oils Capsules & Tablets Infused Drinks Edibles Greater bioavailability (Fast acting, less active needed and less side effects) Precision dosing (consistent, accurate, repeatable) No Irritation (i.e. lung, throat, stomach) Ease of use for improved patient/consumer adherence Safe (no pulmonary/blood pressure issues) Appropriate for Medical / Pharmaceutical Reliable onset of action Pleasant Taste (No after taste, bad breathe) Improved blood-brain circulation, brain function, saliva production, dental health

8 Target Consumer Pain and Inflammation 1 in 5 Canadian Adults suffer from pain Types: Chronic pain, Neuropathic pain, Cancer-related Treatment costs more than $6 billion/yr in Canada 1 Mental Illness 1 in 5 Canadians suffer from mental illness Types: Addiction, Anxiety, Mood & Sleep disorders $43.3 billion was spent in 2011 for treatment, care and support services 2 Health and Wellness Health conscious-consumer seeking alternative solutions to support stress, calm for focus, recovery from exercise, reducing blood sugar levels, reducing seizures/convulsions, and overall general health 1 Canadian Pain Society 2 Mental Health Commission of Canada - Making the Case for Investing in Mental Health in Canada 2013

9 Product Strategy Q Hemp-based CBD chewing gum Build brand awareness & distribution, generate sales, capture user experience 2019 CBD+, THC, THC:CBD, other varieties Build brand, grow sales, expand distribution, user experience, and studies to support Rx market 2019 / 2020 Rx s in Canada and int l markets Build patient database for next generation products and new drug approvals (FDA)

10 Potential Distribution Channels Online Revive site Food, Drug, Mass, Natural & Specialty Other Private Cannabis stores and Health care clinics

11 Robust Cannabinoid Patent Portfolio Chewing Gum Compositions Comprising Cannabinoids Issued CA Patent CA Issued U.S. Patents 9,343,601, 9,023,322 Tannin-Chitosan Issued U.S. Patents 8, and 9, U.S. Patent Application 2017/ Use of Cannabidiol in the Treatment of Autoimmune Hepatitis Issued U.S. Patent 8,242,178 U.S. Patent Application /

12 Future Best-in-Class Products ü Improved bioavailability (avoid GI tract / liver) ü Accelerates reduction of inflammation and healing ü Improved patient compliance ü Sustained / Controlled delivery ü Target large market opportunities Ø Skin disorders Psoriasis, Eczema, Acne Ø Wound care Diabetic ulcers, scars

13 Pharmaceuticals Cannabinoids could represent ~10% of overall specialty pharmaceutical market over next 5 years market size of at least $20 Billion 1 Rare inflammatory diseases Market exclusivity, premium pricing Cannabinoid patents in liver & drug delivery R&D for scientific and clinical validation Pharma partnering potential Pharma Cannabis Leader $4 bn market cap 1 Viridian Capital Advisors. (2015, December 2). REPORT: The Cannabis biotech/pharma market could surpass $20 Billion by 2020.

14 Go Forward Strategy Focus on Growth First mover advantage and best-in-class products SALES INNOVATE INVEST PARTNERS BIZ DEV GROWTH Achieve near-term sales of hemp-based CBD gum Develop & commercialize unique dosages of cannabis gum and topicals Conduct studies (R&D, Clinical) to expand patents, support product claims, Rx extensions Partner with licensed producers, sublicensing Acquisitions, licenses, collaborations, and international markets Innovation, differentiation, high value, validation to accelerate growth

15 Revive Team Management Team Board of Directors Craig Leon Fabio Chianelli Craig Leon Fabio Chianelli Chairman and CEO Titan Medical Chair/CEO Executive President and Director Titan Medical Business Development Chairman and CEO President and Director Operations, Capital Markets Generex BD drug delivery, Licensing, JVs Generex BD/Marketing drug delivery Consumer Health Products William Jackson Carlo Sansalone Carmelo Marrelli Chief Financial Officer CFO to TSX listed firms Dr. Bev Incledon VP, Research and Development Highland Therapeutics, Exec VP, R&D Director CEO of ATTWILL Vascular Technologies LP Medical devices - Karl Stortz, Stryker, Covalon Director Private investor in real estate, construction, Technology and life sciences

16 Valuation Analysis Licensed Producers $12.9 billion $8.1 billion $3.2 billion Life Sciences / Wellness $570 million $190 million $170 million $11 million Pharma $4 billion $575 million $110 million

17 Key Financial Information Ticker Symbols Share Price 52 week High/Low Capital Structure Cash and Cash Equivalents RVV (TSX Venture) RVVTF (OTCQB) 31R (Borse Frankfurt) CAD $0.19 (August 27, 2018) CAD $0.51 / $ ,401,282 common shares (61,869,433 fully-diluted) CAD ~ $11,000,000 CAD $1,287,202 (as of March 31, 2018) Stock Options: 3,468,151 stock options $0.60; $0.66; $0.30; $0.28; $0.20; $0.335; $0.205)